UK Markets closed

Workday, Boeing, Tesla and Airbnb rise premarket; Crowdstrike falls

By Peter Nurse -- Stocks in focus in premarket trade on Wednesday, November 30th. Please refresh for updates.

Crowdstrike (NASDAQ:CRWD) stock slumped 17% after the cybersecurity company disappointed with its outlook for the current quarter, as new revenue growth was weaker than expected.

Workday (NASDAQ:WDAY) stock rose 9.6% after the cloud software firm beat quarterly expectations, a very good result given the economic climate and the spate of layoffs announced by other tech firms.

Biogen (NASDAQ:BIIB) stock rose 3% after the drug company’s experimental Alzheimer's drug, developed jointly with Eisai, slowed cognitive decline in a closely watched trial.

Hewlett Packard Enterprise (NYSE:HPE) stock rose 1.9% after the tech giant delivered a brighter-than-expected outlook for the current quarter and fourth-quarter revenue topped estimates on strong demand for its cloud offering.

Horizon Therapeutics (NASDAQ:HZNP) stock soared 33% after the Wall Street Journal reported the drugmaker is attracting takeover interest from a number of large pharmaceutical companies.

Tesla (NASDAQ:TSLA) stock rose 0.7% after the electric car manufacturer's sales in China nearly doubled in November, from a year earlier, after cutting prices and offering incentives on its Model 3 and Model Y. Boeing (NYSE:BA) stock rose 1.6% after a key U.S. lawmaker proposed an extension of a certification deadline for two new versions of the plane manufacturer's 737 MAX.

Airbnb (NASDAQ:ABNB) stock rose 1% after the online lodging service announced a platform allowing renters to host apartments, partnering with major landlords.

DoorDash (NYSE:DASH) stock rose 1.8% after the food delivery service announced plans to cut around 1,250 jobs in an attempt to rein in costs.

Related Articles

Workday, Boeing, Tesla and Airbnb rise premarket; Crowdstrike falls

Sweden's H&M to lay off 1,500 staff in drive to cut soaring costs and rescue profits

U.S. hedge fund Engine Capital urges Univar to consider sale, other options